How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
54
IRON Quote, Financials, Valuation and Earnings
Last price:
$77.31
Seasonality move
:
-7.32%
Day range:
$75.60 - $79.40
52-week range:
$30.82 - $99.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
5.09x
Volume:
480.2K
Avg. volume:
622.6K
1-year change:
39.06%
Market cap:
$2.9B
Revenue:
--
EPS (TTM):
-$5.36
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IRON
Disc Medicine, Inc.
|
$4.6M | -$1.69 | -- | -84.62% | $122.08 |
|
BSX
Boston Scientific Corp.
|
$5.6B | $0.87 | 11.57% | 76.14% | $124.41 |
|
EBS
Emergent BioSolutions, Inc.
|
$295M | $0.11 | 23.76% | -94.67% | $13.50 |
|
LLY
Eli Lilly & Co.
|
$18.9B | $8.05 | 35.51% | 147.92% | $1,146.30 |
|
MRK
Merck & Co., Inc.
|
$16.5B | $2.13 | 2.47% | -85.55% | $117.58 |
|
PEN
Penumbra, Inc.
|
$387.6M | $1.20 | 14.25% | 8.28% | $348.53 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IRON
Disc Medicine, Inc.
|
$77.32 | $122.08 | $2.9B | -- | $0.00 | 0% | -- |
|
BSX
Boston Scientific Corp.
|
$93.53 | $124.41 | $138.7B | 50.03x | $0.00 | 0% | 7.22x |
|
EBS
Emergent BioSolutions, Inc.
|
$11.34 | $13.50 | $595.6M | 8.76x | $0.00 | 0% | 0.80x |
|
LLY
Eli Lilly & Co.
|
$1,037.15 | $1,146.30 | $928.3B | 51.29x | $1.50 | 0.58% | 15.91x |
|
MRK
Merck & Co., Inc.
|
$110.27 | $117.58 | $273.7B | 14.59x | $0.85 | 2.98% | 4.35x |
|
PEN
Penumbra, Inc.
|
$358.17 | $348.53 | $14.1B | 85.60x | $0.00 | 0% | 10.52x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IRON
Disc Medicine, Inc.
|
5.13% | 1.446 | 1.34% | 23.03x |
|
BSX
Boston Scientific Corp.
|
33.99% | 0.384 | 8.31% | 0.81x |
|
EBS
Emergent BioSolutions, Inc.
|
53.53% | 4.542 | 144.36% | 2.93x |
|
LLY
Eli Lilly & Co.
|
64.11% | -0.496 | 6.22% | 0.65x |
|
MRK
Merck & Co., Inc.
|
44.38% | -0.108 | 20.79% | 1.06x |
|
PEN
Penumbra, Inc.
|
13.77% | -0.892 | 2.19% | 3.87x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IRON
Disc Medicine, Inc.
|
-$87K | -$67.7M | -31.4% | -32.82% | -- | -$47.8M |
|
BSX
Boston Scientific Corp.
|
$3.3B | $1B | 8.19% | 12.46% | 20.55% | $1.2B |
|
EBS
Emergent BioSolutions, Inc.
|
$129.1M | $76.8M | 6.29% | 14.25% | 33.23% | -$5.7M |
|
LLY
Eli Lilly & Co.
|
$14.6B | $8.4B | 33.81% | 106.26% | 47.65% | $6B |
|
MRK
Merck & Co., Inc.
|
$13B | $7.5B | 22.23% | 39.63% | 43.43% | $6.8B |
|
PEN
Penumbra, Inc.
|
$238M | $48.8M | 11.35% | 13.4% | 13.77% | $42M |
Disc Medicine, Inc. vs. Competitors
-
Which has Higher Returns IRON or BSX?
Boston Scientific Corp. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of 14.91%. Disc Medicine, Inc.'s return on equity of -32.82% beat Boston Scientific Corp.'s return on equity of 12.46%.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine, Inc.-- -$1.77 $604.4M BSXBoston Scientific Corp.65.31% $0.50 $35.7B -
What do Analysts Say About IRON or BSX?
Disc Medicine, Inc. has a consensus price target of $122.08, signalling upside risk potential of 57.89%. On the other hand Boston Scientific Corp. has an analysts' consensus of $124.41 which suggests that it could grow by 33.01%. Given that Disc Medicine, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Disc Medicine, Inc. is more attractive than Boston Scientific Corp..
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine, Inc.11 0 0 BSXBoston Scientific Corp.26 1 0 -
Is IRON or BSX More Risky?
Disc Medicine, Inc. has a beta of 0.870, which suggesting that the stock is 13.012% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.
-
Which is a Better Dividend Stock IRON or BSX?
Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or BSX?
Disc Medicine, Inc. quarterly revenues are --, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Disc Medicine, Inc.'s net income of -$62.3M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 50.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus 7.22x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine, Inc.-- -- -- -$62.3M BSXBoston Scientific Corp.7.22x 50.03x $5.1B $755M
-
Which has Higher Returns IRON or EBS?
Emergent BioSolutions, Inc. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of 22.16%. Disc Medicine, Inc.'s return on equity of -32.82% beat Emergent BioSolutions, Inc.'s return on equity of 14.25%.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine, Inc.-- -$1.77 $604.4M EBSEmergent BioSolutions, Inc.55.86% $0.91 $1.3B -
What do Analysts Say About IRON or EBS?
Disc Medicine, Inc. has a consensus price target of $122.08, signalling upside risk potential of 57.89%. On the other hand Emergent BioSolutions, Inc. has an analysts' consensus of $13.50 which suggests that it could grow by 19.05%. Given that Disc Medicine, Inc. has higher upside potential than Emergent BioSolutions, Inc., analysts believe Disc Medicine, Inc. is more attractive than Emergent BioSolutions, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine, Inc.11 0 0 EBSEmergent BioSolutions, Inc.2 0 0 -
Is IRON or EBS More Risky?
Disc Medicine, Inc. has a beta of 0.870, which suggesting that the stock is 13.012% less volatile than S&P 500. In comparison Emergent BioSolutions, Inc. has a beta of 2.300, suggesting its more volatile than the S&P 500 by 129.997%.
-
Which is a Better Dividend Stock IRON or EBS?
Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Emergent BioSolutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. Emergent BioSolutions, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or EBS?
Disc Medicine, Inc. quarterly revenues are --, which are smaller than Emergent BioSolutions, Inc. quarterly revenues of $231.1M. Disc Medicine, Inc.'s net income of -$62.3M is lower than Emergent BioSolutions, Inc.'s net income of $51.2M. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while Emergent BioSolutions, Inc.'s PE ratio is 8.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus 0.80x for Emergent BioSolutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine, Inc.-- -- -- -$62.3M EBSEmergent BioSolutions, Inc.0.80x 8.76x $231.1M $51.2M
-
Which has Higher Returns IRON or LLY?
Eli Lilly & Co. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of 31.72%. Disc Medicine, Inc.'s return on equity of -32.82% beat Eli Lilly & Co.'s return on equity of 106.26%.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine, Inc.-- -$1.77 $604.4M LLYEli Lilly & Co.82.91% $6.21 $66.4B -
What do Analysts Say About IRON or LLY?
Disc Medicine, Inc. has a consensus price target of $122.08, signalling upside risk potential of 57.89%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,146.30 which suggests that it could grow by 9.33%. Given that Disc Medicine, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Disc Medicine, Inc. is more attractive than Eli Lilly & Co..
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine, Inc.11 0 0 LLYEli Lilly & Co.17 7 0 -
Is IRON or LLY More Risky?
Disc Medicine, Inc. has a beta of 0.870, which suggesting that the stock is 13.012% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.185%.
-
Which is a Better Dividend Stock IRON or LLY?
Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IRON or LLY?
Disc Medicine, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Disc Medicine, Inc.'s net income of -$62.3M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus 15.91x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine, Inc.-- -- -- -$62.3M LLYEli Lilly & Co.15.91x 51.29x $17.6B $5.6B
-
Which has Higher Returns IRON or MRK?
Merck & Co., Inc. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of 33.68%. Disc Medicine, Inc.'s return on equity of -32.82% beat Merck & Co., Inc.'s return on equity of 39.63%.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine, Inc.-- -$1.77 $604.4M MRKMerck & Co., Inc.75.59% $2.32 $93.3B -
What do Analysts Say About IRON or MRK?
Disc Medicine, Inc. has a consensus price target of $122.08, signalling upside risk potential of 57.89%. On the other hand Merck & Co., Inc. has an analysts' consensus of $117.58 which suggests that it could grow by 6.54%. Given that Disc Medicine, Inc. has higher upside potential than Merck & Co., Inc., analysts believe Disc Medicine, Inc. is more attractive than Merck & Co., Inc..
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine, Inc.11 0 0 MRKMerck & Co., Inc.14 12 0 -
Is IRON or MRK More Risky?
Disc Medicine, Inc. has a beta of 0.870, which suggesting that the stock is 13.012% less volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.859%.
-
Which is a Better Dividend Stock IRON or MRK?
Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.98% to investors and pays a quarterly dividend of $0.85 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 46.32% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios IRON or MRK?
Disc Medicine, Inc. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $17.2B. Disc Medicine, Inc.'s net income of -$62.3M is lower than Merck & Co., Inc.'s net income of $5.8B. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus 4.35x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine, Inc.-- -- -- -$62.3M MRKMerck & Co., Inc.4.35x 14.59x $17.2B $5.8B
-
Which has Higher Returns IRON or PEN?
Penumbra, Inc. has a net margin of -- compared to Disc Medicine, Inc.'s net margin of 12.93%. Disc Medicine, Inc.'s return on equity of -32.82% beat Penumbra, Inc.'s return on equity of 13.4%.
Company Gross Margin Earnings Per Share Invested Capital IRONDisc Medicine, Inc.-- -$1.77 $604.4M PENPenumbra, Inc.67.1% $1.17 $1.6B -
What do Analysts Say About IRON or PEN?
Disc Medicine, Inc. has a consensus price target of $122.08, signalling upside risk potential of 57.89%. On the other hand Penumbra, Inc. has an analysts' consensus of $348.53 which suggests that it could fall by -2.69%. Given that Disc Medicine, Inc. has higher upside potential than Penumbra, Inc., analysts believe Disc Medicine, Inc. is more attractive than Penumbra, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IRONDisc Medicine, Inc.11 0 0 PENPenumbra, Inc.2 13 1 -
Is IRON or PEN More Risky?
Disc Medicine, Inc. has a beta of 0.870, which suggesting that the stock is 13.012% less volatile than S&P 500. In comparison Penumbra, Inc. has a beta of 0.714, suggesting its less volatile than the S&P 500 by 28.599%.
-
Which is a Better Dividend Stock IRON or PEN?
Disc Medicine, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Penumbra, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Disc Medicine, Inc. pays -- of its earnings as a dividend. Penumbra, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IRON or PEN?
Disc Medicine, Inc. quarterly revenues are --, which are smaller than Penumbra, Inc. quarterly revenues of $354.7M. Disc Medicine, Inc.'s net income of -$62.3M is lower than Penumbra, Inc.'s net income of $45.9M. Notably, Disc Medicine, Inc.'s price-to-earnings ratio is -- while Penumbra, Inc.'s PE ratio is 85.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Disc Medicine, Inc. is -- versus 10.52x for Penumbra, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IRONDisc Medicine, Inc.-- -- -- -$62.3M PENPenumbra, Inc.10.52x 85.60x $354.7M $45.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
